“It will also allow Medtronic to grow revenue and earnings faster without Diabetes than we do with it today.”

How to check this claim

Look at: Medtronic total company revenue growth rate and EPS growth rate (excluding/without Diabetes segment), year-over-year

It came true if: Revenue growth rate and non-GAAP EPS growth rate for the company excluding Diabetes segment, for the period after separation, higher than the comparable company-wide growth rate reported prior to the Diabetes separation

Where: Medtronic quarterly earnings releases and management commentary (10-Q/10-K, earnings call segment disclosures)

Verify independently

SEC filings for MDT ↗ · Claim quote is verbatim from the 2026Q1 earnings call.